ANTX
Price
$1.07
Change
+$0.02 (+1.90%)
Updated
Aug 15 closing price
Capitalization
29.24M
80 days until earnings call
REGN
Price
$580.41
Change
+$14.44 (+2.55%)
Updated
Aug 15 closing price
Capitalization
61.52B
74 days until earnings call
Interact to see
Advertisement

ANTX vs REGN

Header iconANTX vs REGN Comparison
Open Charts ANTX vs REGNBanner chart's image
AN2 Therapeutics
Price$1.07
Change+$0.02 (+1.90%)
Volume$52.87K
Capitalization29.24M
Regeneron Pharmaceuticals
Price$580.41
Change+$14.44 (+2.55%)
Volume$1.12M
Capitalization61.52B
ANTX vs REGN Comparison Chart in %
Loading...
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANTX vs. REGN commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTX is a Hold and REGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (ANTX: $1.07 vs. REGN: $580.41)
Brand notoriety: ANTX: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANTX: 32% vs. REGN: 113%
Market capitalization -- ANTX: $29.24M vs. REGN: $61.52B
ANTX [@Biotechnology] is valued at $29.24M. REGN’s [@Biotechnology] market capitalization is $61.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANTX’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • ANTX’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than ANTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANTX’s TA Score shows that 3 TA indicator(s) are bullish while REGN’s TA Score has 7 bullish TA indicator(s).

  • ANTX’s TA Score: 3 bullish, 5 bearish.
  • REGN’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, REGN is a better buy in the short-term than ANTX.

Price Growth

ANTX (@Biotechnology) experienced а -0.93% price change this week, while REGN (@Biotechnology) price change was +3.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

ANTX is expected to report earnings on Nov 06, 2025.

REGN is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($61.5B) has a higher market cap than ANTX($29.2M). REGN YTD gains are higher at: -18.294 vs. ANTX (-22.464). REGN has higher annual earnings (EBITDA): 5.42B vs. ANTX (-47.8M). REGN has more cash in the bank: 7.47B vs. ANTX (67.1M). REGN has higher revenues than ANTX: REGN (14.2B) vs ANTX (0).
ANTXREGNANTX / REGN
Capitalization29.2M61.5B0%
EBITDA-47.8M5.42B-1%
Gain YTD-22.464-18.294123%
P/E RatioN/A14.63-
Revenue014.2B-
Total Cash67.1M7.47B1%
Total DebtN/A2.71B-
FUNDAMENTALS RATINGS
ANTX vs REGN: Fundamental Ratings
ANTX
REGN
OUTLOOK RATING
1..100
5015
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9755
PRICE GROWTH RATING
1..100
6063
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
5048

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (4) in the Biotechnology industry is in the same range as ANTX (10) in the Managed Health Care industry. This means that REGN’s stock grew similarly to ANTX’s over the last 12 months.

REGN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ANTX (100) in the Managed Health Care industry. This means that REGN’s stock grew similarly to ANTX’s over the last 12 months.

REGN's SMR Rating (55) in the Biotechnology industry is somewhat better than the same rating for ANTX (97) in the Managed Health Care industry. This means that REGN’s stock grew somewhat faster than ANTX’s over the last 12 months.

ANTX's Price Growth Rating (60) in the Managed Health Care industry is in the same range as REGN (63) in the Biotechnology industry. This means that ANTX’s stock grew similarly to REGN’s over the last 12 months.

REGN's P/E Growth Rating (95) in the Biotechnology industry is in the same range as ANTX (100) in the Managed Health Care industry. This means that REGN’s stock grew similarly to ANTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANTXREGN
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
46%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
74%
Momentum
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
65%
MACD
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
64%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
63%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
61%
Declines
ODDS (%)
Bearish Trend 8 days ago
84%
Bearish Trend 13 days ago
55%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
55%
Aroon
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
ANTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRI171.323.51
+2.09%
Thomson Reuters Corp
MZTI180.29-1.07
-0.59%
The Marzetti Company
EPC22.93-0.33
-1.42%
Edgewell Personal Care Company
III4.86-0.11
-2.21%
Information Services Group
NTRP3.55-0.30
-7.79%
NextTrip

ANTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANTX has been loosely correlated with ROIV. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ANTX jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANTX
1D Price
Change %
ANTX100%
+1.42%
ROIV - ANTX
35%
Loosely correlated
+0.85%
SNBIF - ANTX
33%
Loosely correlated
N/A
PASG - ANTX
32%
Poorly correlated
-8.43%
REGN - ANTX
30%
Poorly correlated
+2.55%
FBRX - ANTX
29%
Poorly correlated
+6.93%
More

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with ROIV. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+2.55%
ROIV - REGN
42%
Loosely correlated
+0.85%
IDYA - REGN
40%
Loosely correlated
-0.16%
TECH - REGN
40%
Loosely correlated
-0.26%
SMMT - REGN
39%
Loosely correlated
+0.91%
ACLX - REGN
39%
Loosely correlated
+3.09%
More